Hutchmed (China) Limited

Remuneration Information • Oct 21, 2025

National Storage Mechanism | Additional information

RNS Number : 0510E

Hutchmed (China) Limited

21 October 2025

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ - Tuesday, October 2 1 , 2025: HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on October 20, 2021 to the following persons discharging managerial responsibilities were vested on October 2 0 , 2025:-

Award Holder		Number of American depositary shares ("ADS")
Dr Dan Eldar (Non-executive Director ("NED"))		1,938
Ms Edith Shih (NED)		1,938 (1)
Professor Tony Mok (Independent Non-executive Director)		1,938

Note:

(1)   These ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

(a) Dr Dan Eldar

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr Dan Eldar

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HUTCHMED (China) Limited

b)

LEI

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

ADS ISIN: US44842L1035

b)

Nature of the transaction

Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP

c)

Price(s) and volume(s)

Price(s)	Volume(s)
Nil	1,938 ADS

d)

Aggregated information

-	Aggregated volume
-	Price

N/A

e)

Date of the transaction

2025-10-2 0

f)

Place of the transaction

Outside a trading venue

(b) Professor Tony Mok

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Professor Tony Mok

2

Reason for the notification

a)

Position/status

Independent Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

HUTCHMED (China) Limited

b)

LEI

2138006X34YDQ6OBYE79

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

ADS ISIN: US44842L1035

b)

Nature of the transaction

Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP

c)

Price(s) and volume(s)

Price(s)	Volume(s)
Nil	1,938 ADS

d)

Aggregated information

-	Aggregated volume
-	Price

N/A

e)

Date of the transaction

2025-10-2 0

f)

Place of the transaction

Outside a trading venue

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

CONTACTS

##### Investor Enquiries	+852 2121 8200 / [email protected]
##### Media Enquiries
FTI Consulting -	+44 20 3727 1030 / [email protected]
Ben Atwell / Alex Shaw	+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
Brunswick - Zhou Yi	+852 9783 6894 (Mobile) / [email protected]
##### Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
##### Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
##### Deutsche Numis	Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith	+44 20 7260 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDZMZGGGRGKZM